<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670862</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT-ChinaPLAGH</org_study_id>
    <nct_id>NCT03670862</nct_id>
  </id_info>
  <brief_title>Prediction Model for the Recanalization OuTcome Evaluation of Ischemic Stroke Using Multimodal CT</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Prediction Model for the Recanalization Outcome Evaluation of Ischemic Stroke Using Multimodal CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prediction model for the Recanalization OuTcome Evaluation of ischemic stroke using&#xD;
      multimodal CT (PROTECT) study was a multicenter prospective observational study that&#xD;
      recruited patients from 13 centers located in 10 provinces across China. The study was to&#xD;
      assess the effects of novel imaging biomarkers/ imaging patterns based on multimodel CT for&#xD;
      patients selection and outcome prediction in acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients Patients with cerebral ischemia symptoms of anterior circulation or posterior&#xD;
      circulation onset in 24 hours were included. A neurological evaluation (Modified Rankin Scale&#xD;
      and NIHSS); physical examination, including measurement of weight (kg) and vital signs&#xD;
      (supine systolic and diastolic blood pressure); time from symptom onset to enrollment were&#xD;
      recorded.&#xD;
&#xD;
      Imaging protocols:&#xD;
&#xD;
      CT scan protocols: Non-contrast computed tomography(NCCT) , computed tomography&#xD;
      angiography(CTA), computed tomography perfusion(CTP)&#xD;
&#xD;
      Contrast agent:&#xD;
&#xD;
      CTA: Omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s&#xD;
&#xD;
      CTP: Omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s&#xD;
&#xD;
      Imaging evaluation:&#xD;
&#xD;
      CTA was reviewed and stenosis or occlusive lesions were identified. Parameter maps including&#xD;
      cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the&#xD;
      residue function derived from CTP were processed by the software Rapid to quantitatively&#xD;
      assess infarct core volume and mismatch.&#xD;
&#xD;
      Multiphase CTA was extracted from CTP to evaluate the collateral circulation.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy, and&#xD;
      conventional treatment including neuroprotection, anti-platelet, and statin according to the&#xD;
      guideline.&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
      Modified Rankin Scale(mRS) was obtained at 90 days after symptom onset. An imaging follow-up&#xD;
      was also recommended within 30 days after symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>90-day functional outcome</measure>
    <time_frame>90 days after symptom onset</time_frame>
    <description>Assessed by modified Rankin Scale with scores ranging from 0 (no symptoms) to 6 (death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final infarction volume</measure>
    <time_frame>within 30 days after symptom onset</time_frame>
    <description>Finding the predictive value of novel imaging biomarkers/ imaging patterns on final infarction volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Hemorrhagic Transformation</measure>
    <time_frame>within 7 days after symptom onset</time_frame>
    <description>Symptomatic hemorrhagic transformation after acute ischemic stroke</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">862</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>stroke</arm_group_label>
    <description>Ischemic stroke patients with sympton onset in 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging</description>
    <arm_group_label>stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ischemic stroke patients with sympton onset in 24 hours&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cerebral ischemic sympton with onset in 24 hours&#xD;
&#xD;
          -  All CT examination performed according to study protocol&#xD;
&#xD;
          -  Signed informed consent obtained from the patient or patient's legally authorized&#xD;
             representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute intracranial hemorrhage&#xD;
&#xD;
          -  Pre-existing medical, the neurological, or psychiatric disease that would confound the&#xD;
             neurological, functional, or imaging evaluations&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known allergy to iodine previously refractory to pretreatment medications&#xD;
&#xD;
          -  Renal Failure (serum creatinine &gt; 2.0 or Glomerular Filtration Rate &lt; 30)&#xD;
&#xD;
          -  History of severe kidney disease as an adult, including tumor or transplant surgery,&#xD;
             or family history of kidney failure&#xD;
&#xD;
          -  Severe cardiac insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Lou, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xin Lou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ischemic stroke</keyword>
  <keyword>CTP</keyword>
  <keyword>CTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

